Authors
Jessica N Strosahl, Amber Malik, Rani H Singh
Published in
Current opinion in clinical nutrition and metabolic care. Nov 06, 2026. Epub Nov 06, 2026.
Abstract
Maternal phenylketonuria (PKU) management has appropriately centered on restricting dietary phenylalanine (Phe) to prevent fetal toxicity. This review argues that the next advance should be to define what must be provided: trimester-appropriate total protein, a complete essential amino acid pattern, controlled but not deficient Phe, and sustained tyrosine availability.
Direct studies in healthy pregnancy suggest that protein requirements rise from approximately 1.22 g/kg/day in early gestation to 1.52 g/kg/day in late gestation, while requirements for individual amino acids do not increase uniformly. These findings challenge fixed protein prescriptions in maternal PKU, where a substantial proportion of protein may be delivered as rapidly absorbed free amino acids, and current guideline adjustments of 20-40% above reference protein intakes remain consensus based. Recent maternal PKU reports suggest that Phe tolerance cannot be predicted reliably from gestational stage or fetal genotype, and the increasing availability of Phe-lowering therapies heightens concerns about Phe insufficiency. Fixed daily tyrosine targets likewise do not address diurnal fluctuation and the need for sustained availability.
Maternal PKU nutrition should move beyond Phe restriction alone toward precision provision of protein and amino acids across gestation, with attention to quantity, quality, source, timing, and utilization to optimize maternal and fetal health.
PMID:
42989926
Bibliographic data and abstract were imported from PubMed on 06 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0